(Q44597027)

English

Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity

scientific article published on October 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity (English)

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prenatal exposure delayed effects

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510821

14 March 2024

animal disease model

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510821

14 March 2024

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Richard H. Finnell

10

object named as

Richard H. Finnell

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510821

14 March 2024

author name string

Nina Isoherranen

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Ofer Spiegelstein

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Meir Bialer

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Jing Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Michelle Merriweather

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Boris Yagen

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Michael Roeder

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Volker Schurig

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Aleata A. Triplett

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510821

14 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14510821

14 March 2024

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1528-1157.2003.21503.x

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1528-1157.2003.21503.x

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1280-1288

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Use of levetiracetam in special populations

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2003.21503.X

21 January 2018

Prenatal prediction of risk of the fetal hydantoin syndrome

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2003.21503.X

21 January 2018

Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).

1

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Levetiracetam. A review of its adjunctive use in the management of partial onset seizures

2

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Levetiracetam: A new antiepileptic drug for the adjunctive therapy of chronic epilepsy

3

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes

4

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

5

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles

8

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Congenital malformations due to antiepileptic drugs

9

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: Human studies

10

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Genetic differences in susceptibility to anticonvulsant drug-induced developmental defects

11

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Mechanism of known environmental teratogens: drugs and chemicals.

14

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation

17

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis.

18

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

19

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent

20

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Anticonvulsant teratogenesis: 3. Possible metabolic basis

21

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs

23

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography

26

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Bioanalytical method validation--a revisit with a decade of progress

27

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite.

28

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Valproic Acid-Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible Mechanisms

30

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre.

31

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Phenytoin-induced teratogenesis: a molecular basis for the observed developmental delay during neurulation.

32

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Strain differences in phenobarbital-induced teratogenesis in mice

33

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model.

34

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats

35

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Fetal hydantoin syndrome in rats: dose-effect relationships of prenatal phenytoin on postnatal development and behavior

36

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

New antiepileptic drugs in pregnancy: outcome of 12 exposed pregnancies

37

1 reference

10.1046/J.1528-1157.2003.21503.X

https://api.crossref.org/works/10.1046/J.1528-1157.2003.21503.X

14 March 2024

Identifiers

10.1046/J.1528-1157.2003.21503.X

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44597027&oldid=2101943305"